Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting

Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720–4.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–18.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Laetsch TW, Myers GD, Baruchel A, Dietz AC, Pulsipher MA, Bittencourt H, et al. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial. Lancet Oncol. 2019;20(12):1710–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020;4(21):5414–24.

CAS  PubMed  PubMed Central  Article  Google Scholar 

John S, Pulsipher MA, Moskop A, Hu Z-H, Phillips CL, Hall EM, et al. Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 2021;138(Supplement 1):428.

Article  Google Scholar 

Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, et al. KMT2A rearrangements are associated with lineage switch following CD19 targeting CAR T-cell therapy. Blood. 2021;138(Supplement 1):256.

Article  Google Scholar 

Zhang X, Zhang G, Li W, Zhang Y, Wang T, Yang J, et al. Factors associated with outcomes among refractory/relapsed TP53-mutated/chromosome 17p deletion acute B-cell lymphoblastic leukemia (B-ALL) patients treated with CD19-targeted chimeric antigen receptor (CAR)-T therapy. Blood. 2021;138(Supplement 1):3828.

Article  Google Scholar 

Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449–59.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, et al. CD19 CAR T cell product and disease attributes predict leukemia remission durability. J Clin Invest. 2019;129(5):2123–32.

PubMed  PubMed Central  Article  Google Scholar 

Gabelli M, Oporto Espuelas M, Bonney D, Burridge S, Farish S, Mullanfiroze K, et al. ALL maintenance treatment for early loss of B-cell aplasia after tisagenlecleucel therapy. Blood. 2021;138(Supplement 1):3859.

Article  Google Scholar 

Nie Y, Lu W, Chen D, Tu H, Guo Z, Zhou X, et al. Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomark Res. 2020;8:18.

PubMed  PubMed Central  Article  Google Scholar 

Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, et al. Outcomes after reinfusion of CD19-specific chimeric antigen receptor (CAR)-modified T cells in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):474.

Article  Google Scholar 

Pan J, Zuo S, Deng B, Xu X, Li C, Zheng Q, et al. Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. Blood. 2020;135(5):387–91.

PubMed  Article  Google Scholar 

Wang N, Hu X, Cao W, Li C, Xiao Y, Cao Y, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood. 2020;135(1):17–27.

PubMed  Article  Google Scholar 

Amrolia PJ, Wynn R, Hough RE, Vora A, Bonney D, Veys P, et al. Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): Amelia Study. Blood. 2019;134(Supplement_1):2620.

Article  Google Scholar 

Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med. 2021;27(10):1797–805.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Zhao J, Song Y, Liu D. Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia. J Hematol Oncol. 2019;12(1):17.

PubMed  PubMed Central  Article  Google Scholar 

Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):30.

PubMed  PubMed Central  Article  Google Scholar 

Annesley C, Summers C, Pulsipher MA, Skiles JL, Li AM, Vatsayan A, et al. SCRI-CAR19x22v2 T cell product demonstrates bispecific activity in B-ALL. Blood. 2021;138(Supplement 1):470.

Article  Google Scholar 

Frey NV, Gill S, Hwang W-T, Luger SM, Martin ME, McCurdy SR, et al. CART22-65s co-administered with huCART19 in adult patients with relapsed or refractory ALL. Blood. 2021;138(Supplement 1):469.

Article  Google Scholar 

Yan LE, Zhang H, Wada M, Fang L, Feng J, Zhang W, et al. Targeting two antigens associated with B-ALL with CD19-CD123 compound car T cell therapy. Stem Cell Rev Rep. 2020;16(2):385–96.

CAS  PubMed  Article  Google Scholar 

Zhou Z, Han Y, Pan H-B, Sang C-J, Shi D-L, Feng C, et al. Tri-specific CD19xCD20xCD22 VHH CAR-T cells (LCAR-AIO) eradicate antigen-heterogeneous B cell tumors, enhance expansion, and prolong persistence in preclinical in vivo models. Blood. 2021;138(Supplement 1):1700.

Article  Google Scholar 

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017;377(26):2545–54.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45–56.

CAS  PubMed  Article  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42.

CAS  PubMed  Article  Google Scholar 

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–52.

PubMed  Article  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Landsburg DJ, Frigault MJ, Hu Z-H, Jaglowski S, Locke FL, Ho C, et al. Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin’s lymphoma (aBNHL) treated with commercial tisagenlecleucel: update from the center for international blood and marrow transplant research (CIBMTR) registry. Blood. 2021;138(Supplement 1):429.

Article  Google Scholar 

Jacobson C, Locke FL, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term (≥4 year and ≥5 year) overall survival (OS) by 12- and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma (LBCL). Blood. 2021;138(Supplement 1):1764.

Article  Google Scholar 

Spiegel JY, Jain MD, Nastoupil L, Tamaresis J, Ghobadi A, Lin Y, et al. Long-term outcomes of patients with large B-cell lymphoma treated with standard-of-care axicabtagene ciloleucel: results from the US lymphoma CAR-T cell consortium. Blood. 2021;138(Supplement 1):3826.

Article  Google Scholar 

Di Blasi R, Le Gouill S, Bachy E, Cartron G, Beauvais D, Le Bras F, et al. Outcome of relapsed/refractory aggressive B-cell lymphoma patients relapsing after anti-CD19 CAR T-cells and enrolled in the Descar-T French National Registry. Blood. 2021;138(Supplement 1):885.

Article  Google Scholar 

Ping N, Qu C, Li M, Kang L, Kong D, Chen X, et al. Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma. Ann Transl Med. 2022;10(6):298.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Mu J, Deng H, Lyu C, Yuan J, Li Q, Wang J, et al. Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden. Hematol Oncol. 2022. https://doi.org/10.1002/hon.2981.

Article  PubMed  Google Scholar 

Locke FL, Miklos DB, Jacobson C, Perales M-A, Kersten MJ, Oluwole OO, et al. Primary analysis of ZUMA-7: a phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care therapy in patients with relapsed/refractory large B-cell lymphoma. Blood. 2021;138(Supplement 1):2.

Article  Google Scholar 

Elsawy M, Chavez JC, Avivi I, Larouche J-F, Wannesson L, Cwynarski K, et al. Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (Axi-Cel) versus standard of care therapy in patients with relapsed/refractory large B-cell lymphoma (ZUMA-7). Blood. 2021;138(Supplement 1):430.

Article  Google Scholar 

Kamdar M, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene Maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 transform study. Blood. 2021;138(Supplement 1):91.

Article  Google Scholar 

Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-hodgkin lymphoma: analysis of the phase III Belinda Study. Blood. 2021;138(Supplement 2):LBA-6.

留言 (0)

沒有登入
gif